Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

Presentation underscores unique potential for atrioventricular interval modulation ('AVIM') therapy to manage blood pressure in older, high-risk patients who have indicators of diastolic dysfunction and progression to heart failure with preserved ejection fraction ('HFpEF')
Hypertensive heart disease represents over 7.7 million U.S. patients, the same population with hypertension and elevated cardiovascular risk cited in the recent FDA Breakthrough Device Designation ('BDD') for AVIM therapy
NEW HOPE, Pa., June 18, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, 'Orchestra BioMed' or the 'Company'), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the presentation of key clinical insights into the role of AVIM therapy for the treatment of high-risk hypertension at the Congenital, Structural, and Valvular Heart Disease Interventions ('CSI') 2025 Meeting. The data highlight AVIM therapy's unique potential to address hypertensive heart disease, a significant and under-recognized cardiovascular syndrome that affects a growing segment of the aging hypertension population.
The talk, 'Atrioventricular Interval Modulation (AVIM) Therapy for Hypertension and HFpEF,' will be delivered by Daniel Burkhoff, M.D., Ph.D., Director of Heart Failure, Hemodynamics and Mechanical Circulatory Support Research at Cardiovascular Research Foundation and clinical advisor to Orchestra BioMed. Dr. Burkhoff will spotlight the clinical utility of AVIM therapy as a novel, device-based approach to blood pressure management designed specifically for patients with hypertensive heart disease. This population has increased risk for major adverse cardiac events and currently lacks sufficient therapeutic options. The presentation will take place on June 18, 2025, at 3:33pm CEST / 9:33am ET as part of the ' Interventions for Chronic Heart Failure ' session.
Dr. Burkhoff commented, 'Hypertensive heart disease is not a singular diagnosis, but a high-risk cardiovascular syndrome driven by longstanding, uncontrolled high blood pressure which significantly increases the likelihood of adverse clinical outcomes such as stroke, myocardial infarction, diastolic dysfunction and progression to heart failure. The data I will review at CSI explore how AVIM therapy may offer a unique treatment specifically catered to this group of patients leveraging a mechanism of action designed to reduce cardiac preload and modulate autonomic nervous system responses to reduce blood pressure and improve cardiovascular function. This represents a potential paradigm shift in how we approach blood pressure management using tailored interventions designed to directly impact the complex pathophysiology of high-risk hypertension.'
The presentation will cover: The clinical burden and therapeutic gaps in managing patients with high-risk hypertension and increased risk of heart failure;
in managing patients with high-risk hypertension and increased risk of heart failure; The growing body of clinical and mechanistic evidence demonstrating AVIM therapy's potential to lower blood pressure and improve cardiac function; and
demonstrating AVIM therapy's potential to lower blood pressure and improve cardiac function; and Details on the BACKBEAT global pivotal study, currently enrolling patients with uncontrolled hypertension who are indicated for a dual-chamber pacemaker. The study is being conducted in collaboration with Medtronic, the global leader in cardiac pacing therapy.
'AVIM therapy was purpose-built to address the complex and underserved needs of patients with hypertensive heart disease, a subgroup often overlooked by conventional therapy,' said Avi Fischer, M.D., Senior Vice President of Medical Affairs and Innovation at Orchestra BioMed. 'As a programmable, pacemaker-integrated solution, AVIM therapy has the potential to fit seamlessly into existing electrophysiology practices while opening the door to better outcomes in a large, underserved population. Dr. Burkhoff's presentation at CSI Frankfurt further reinforces the growing clinical interest in AVIM therapy and highlights the significant opportunity to transform care of hypertensive heart disease, especially given our recently granted BDD status, which applies directly to this patient profile.'
About Orchestra BioMed
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed's partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed's lead product candidate is AVIM therapy for the treatment of hypertension, the leading risk factor for death worldwide. Orchestra BioMed is also developing Virtue SAB for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. The Company has received four Breakthrough Device Designations from the U.S. FDA across these two core programs, reflecting the significant potential of its technologies to address high unmet needs in cardiovascular care. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com , and follow us on LinkedIn .
References to Websites and Social Media Platforms
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.
About AVIM Therapy
AVIM therapy is an investigational therapy compatible with standard dual-chamber pacemakers designed to substantially and persistently lower blood pressure. It has been evaluated in pilot studies in patients with hypertension who are also indicated for a pacemaker. MODERATO II, a double-blind, randomized pilot study, showed that patients treated with AVIM therapy experienced net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure (aSBP) and 12.3 mmHg in office systolic blood pressure (oSBP) at six months when compared to control patients. In addition to reducing blood pressure, clinical results using AVIM therapy demonstrate improvements in cardiac function and hemodynamics. The BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) global pivotal study will further evaluate the safety and efficacy of AVIM therapy in lowering blood pressure in patients who have systolic blood pressure above target despite anti-hypertensive medication and who are indicated for or have recently received a dual-chamber cardiac pacemaker. AVIM therapy has been granted Breakthrough Device Designation by the FDA for the treatment of uncontrolled hypertension in patients who have increased cardiovascular risk.
Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the enrollment, implementation and design of the Company's planned and ongoing pivotal trials, realizing the clinical and commercial value of the Company's product candidates, the potential safety and efficacy of the Company's product candidates, and the ability of the Company's partnerships to accelerate clinical development. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company's commercial product candidates and ongoing regulation of the Company's product candidates, if approved; the timing of, and the Company's ability to achieve expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading 'Item 1A. Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 31, 2025 and the risk factor discussed under the heading 'Item 1A. Risk Factors' in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, which was filed with the SEC on May 12, 2025.
The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.
Investor ContactSilas NewcombOrchestra BioMed
[email protected]

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

43 minutes ago

• Yahoo

BMO says lenacapavir approval for prevention a ‘major win' for Gilead

Although largely as expected by investors, BMO Capital says lenacapavir's approval for prevention, now known as Yeztugo, marks 'a major win for Gilead (GILD)' in driving meaningful growth in its pre-exposure prophylaxis business. A clean label, strong clinical data, and a convenient twice yearly dosing regimen, in line with patient physician visits, should drive strong commercial adoption for Yeztugo, says the analyst, who has an Outperform rating and $120 price target on Gilead shares. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GILD: Disclaimer & DisclosureReport an Issue Cautious Optimism for Gilead Sciences Amid Yeztugo's Market Challenges Morgan Stanley says FDA approval of Yeztugo 'an expected positive' for Gilead Mizuho says Gilead Yeztugo label looks clean Gilead Sciences' Yeztugo Approval and Market Expansion Drive Buy Rating Gilead announces FDA approves Yeztugo as twice-a-year HIV prevention option

Forbes

2 hours ago

• Forbes

Technology Has A Role To Play As Research Adapts To New Constraints

Jiang Li, Ph.D., is the Founder and CEO of Vivalink, Inc. Hybrid and decentralized clinical trials (DCTs) have been gaining momentum in recent years. Following the pandemic, sponsors and regulators increasingly adopted remote-friendly designs, regulatory agencies encouraged their adoption and digital health companies developed tools to facilitate these trials.​ In 2023, the FDA issued draft guidance on DCTs that promoted the use of decentralized elements, such as remote data collection, telehealth visits and wearable sensors, to enhance trial flexibility, efficiency and inclusivity. This guidance was finalized in September 2024, solidifying the FDA's support for incorporating decentralized elements in clinical trials. Policy shifts threaten progress. That momentum is now under pressure. The National Institutes of Health (NIH) funds the bulk of medical research in the U.S. But a new federal policy would cap overhead reimbursement at 15%, reducing indirect cost support for many research centers and potentially reshaping how academic science is funded. Plus, the Department of Health and Human Services has begun cutting nearly 10,000 employees and plans to eliminate a total of 20,000 positions. The layoffs, part of a sweeping restructuring effort, have already impacted core health agencies like the NIH and FDA. As a result, trials have been paused, grants delayed and many research institutions, including major universities and academic medical centers, have reduced staff or scaled back operations. These shifts have posed major challenges for the implementation of DCTs in academic and early-stage research, where adoption was just beginning to gain traction. With fewer staff and less funding, institutions face greater barriers to adopting and managing the technologies essential to decentralized trial models. Yet regulatory support for DCTs, and the need for efficient and accessible trials, haven't gone away. Technology alone can't offset these setbacks, but it can help support ongoing research by reducing operational burden, enabling remote participation and helping sponsors manage studies with fewer resources. Prioritize interoperability. The increased application of DCTs has introduced a growing array of tools into how research is conducted, including wearables, remote monitoring devices, telehealth platforms, mobile apps and dashboards. But as academic institutions and research centers face staffing cuts and constrained budgets, managing a patchwork of disconnected systems is increasingly unsustainable. This environment heightens the need to prioritize interoperability. Even before these changes, sponsors were leaning toward solutions that integrate easily into their existing workflows. Now, they're looking for platforms that reduce the operational burden on already stretched teams. Interoperability should be a core design consideration. Solutions that connect with EHRs, lab systems, participant-reported outcomes and sponsor dashboards can reduce friction, cut down on manual processes and allow research teams to focus on science instead of system management. Equally important are ready-to-use mobile apps and connected devices that require minimal setup or IT support. Planning for integration early, both across systems and devices, can help trials run more efficiently as organizations adapt to doing more with less. Deliver measurable impact. With tighter budgets and increased scrutiny, sponsors need to justify every dollar. That means technology must deliver clear and measurable results, whether by accelerating recruitment, improving retention, reducing site visits or producing more complete datasets. Flexibility is just as important. As trials evolve, sponsors need platforms that can adapt, such as being able to adjust mid-study, support multiple arms or accommodate late-stage protocol changes. Tools that can be configured on the fly or deployed across different trial designs help teams stay responsive when timelines shift or priorities change. Real-time monitoring and continuous data collection are shifting how sponsors track progress during a trial. These technologies often surface early insights and preliminary findings faster than traditional timelines would. As a result, teams now have an opportunity to adjust mid-study, including changes to the study design, resource allocation or cohort size. A recent study highlighted this need for adaptability, pointing to modular digital platforms as a way for sponsors to retain control when trial activities shift. But it also made clear that technology alone isn't enough. As these platforms evolve, clinical and technical teams will need to work together to build solutions that meet the needs of everyone involved, from investigators and sponsors to participants. Technology providers that offer both measurable impact and flexibility, without locking sponsors into rigid ecosystems, are better positioned to support research teams under pressure. Support what remains. Recent funding cuts are disrupting the infrastructure supporting early-stage and academic research, from lab space and shared equipment to staff and resources. While technology can't reverse these cuts, it can support the trials that continue and help sponsors maintain critical metrics like participant adherence. Studies have shown that technology solutions like remote monitoring and digital platforms can increase patient adherence. For example, a recent study using electronic diaries resulted in compliance rates of up to 94%, compared to just 11% with paper diaries. Another study found that remote patient monitoring has been proven to improve adherence to medications and lifestyle changes. Platforms that can track adherence in real time, send automated reminders and flag protocol deviations give research teams the visibility they need to act quickly. These systems can alert teams when a participant's device isn't sending data as expected, track whether devices are being used correctly and help staff identify participants who may need follow-up. With fewer team members and more limited oversight, access to this information is important. As research institutions shift from growth to preservation, technology is playing a more functional role. Technology can't replace the research that's been paused or the teams that have been downsized, but it can help keep ongoing trials on track. That includes maintaining data quality, flagging issues early and helping teams follow up when participants miss visits or fall behind. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?

Yahoo

2 hours ago

• Yahoo

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib CHICAGO and FORT WORTH, Texas, June 20, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) ('Actuate' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced biomarker data from a recent poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metastatic pancreatic adenocarcinoma (mPDAC). The study demonstrated the use of machine learning and statistical models to predict overall survival (OS) based on pre-dose plasma biomarkers. The poster described an analysis of 40 cytokines, chemokines, soluble cell receptors, and growth factors (CCSGs) from plasma samples obtained prior to treatment from all patients enrolled in Actuate-1801 Part 3B. The analysis identified 7 biomarkers as uniquely significant predictors of favorable survival in the elraglusib-treated cohort, including one, CXCL2, with an inverse survival trend compared to the GnP control arm. This indicates that in patients not treated with elraglusib, high CXCL2 was unfavorable, but this trend is reversed with elraglusib treatment, highlighting the potential of elraglusib to favorably affect the immune microenvironment. Univariate analysis revealed strong predictive performance with CXCL2 emerging as a consistently reliable biomarker for survival across multiple cross-validation analyses. Elevated levels of CXCL2 and TRAIL were associated with improved OS, while lower levels of CCL3, IL-1α, IL-18, TGF-β, and TRAIL R3 were similarly linked to better survival. These signatures were combined into multivariate machine learning models that accurately predicted patients who would survive for greater than one year if treated with elraglusib and GnP. 'These results represent an important advance in our biomarker strategy,' said Daniel Schmitt, President & Chief Executive Officer of Actuate. 'They support the ability to use simple, non-invasive blood-based markers to potentially identify patients more likely to benefit from elraglusib. The pre-dose biomarker signatures identified in the 1801 Part 3B study, particularly involving high CXCL2 and low TGF-β, CCL3, and IL-18, which were all associated with a survival benefit, suggests that elraglusib may exert pleiotropic immunomodulatory effects regulating cytotoxic T cells, NK cells and cells of the myeloid lineage including macrophages and neutrophils. Crosstalk between components of the immune system support the growing body of evidence that elraglusib enhances immune response mechanisms critical to its antitumor efficacy.' 'The application of unbiased mathematical and machine learning models allowed us to pinpoint the strongest biomarker signals free from pre-conceived notions of elraglusib's mechanisms. What is so exciting about this project is that the unbiased approach aligns with prior mechanistic studies. The congruence of our clinical data analytics and the preclinical research combined with the strength of our predictive models gives us confidence that these biomarkers could be extremely beneficial in identifying the right patients at the right time,' said Taylor Weiskittel, MD, Ph.D., the lead author on this study. 'We look forward to applying this approach to guide the development of elraglusib in mPDAC as well as other advanced cancer indications in the future.' The company plans to test the identified biomarkers prospectively in future trials. Additional efforts will focus on optimizing sequential univariate combinations for patient stratification, refining multivariate machine learning models for predictive accuracy, and comparing these approaches head-to-head. About Actuate Therapeutics, Inc. Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate's lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function. For additional information, please visit the Company's website at Forward-Looking Statements This press release contains forward-looking statements about us, including our and other parties' clinical trials and development plans, and our industry. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'ongoing,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would,' or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that preliminary and unpublished data including biomarker studies may be subject to change and further interpretation following the availability of more data or following a more comprehensive review of the data and should not be relied upon as a final analysis; clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies, early clinical trials, machine learning and predictive modeling are not necessarily predictive of future results and may not correlate with improved responses, and elraglusib may not achieve positive clinical results or favorable preclinical results or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose for such development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities, including because our financial condition raises substantial doubt as to our ability to continue as a going concern and we require additional capital to finance our operations beyond the second quarter of fiscal year 2025, and a failure to obtain this necessary capital in the near term on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading 'Item 1A. Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 15, 2025, and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events. Investor Contact Mike MoyerManaging DirectorLifeSci Advisors, LLCmmoyer@ Media Contact Ignacio Guerrero-Ros, Ph.D., or David SchullRusso Partners, 717-2310 or (646) 942-5604Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data